Prostate cancer (PCa) is dependent on androgens for growth. Androgen deprivation therapy (ADT) curtails PCa progression, however this powerful selective pressure leads to aggressive, castrate resistant PCa. One castrate resistant prostate cancer subtype, neuroendocrine (NE) PCa, is characterised by increased abundance of NE cells. Transdifferentiation into androgen independent NE-like cells is thought to allow PCa epithelial cells to escape potent ADT, causing resistance. NE-like cells are thought to promote growth of surrounding tumour cells through...